跳至主要内容
临床试验/NCT00196066
NCT00196066已完成2 期

Evaluation of the Zilver Vascular Stent in the Iliac Arteries (ZIPS)

Cook Group Incorporated0 个研究点目标入组 150 人开始时间: 2002年10月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
150
主要终点
The primary endpoint of the study is major adverse event (MAE) rate at the 9-month follow-up.

研究概览

简要总结

The purpose of this study is to assess the ability of a vascular stent to maintain an open iliac (leg) artery. The Zilver Vascular Stent is made of nitinol, a flexible metal with a long history of use in medical devices. The stent self-expands once inside the artery where it is intended to hold the vessel wall open. Within a few weeks, a layer of cells will grow over the stent helping to hold it in place.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient has documented stenotic or occluded atherosclerotic lesions of the external iliac or common iliac artery.
  • Patient has a de novo or restenotic lesion(s) with no prior stent in the target lesion.
  • Patient has given informed consent.

排除标准

  • Patient is less than 50 years of age
  • Patient is participating in another investigational drug or device study.
  • Patient has multiple lesions (ipsilateral or in the aorta) that would require a staged procedure.
  • Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
  • Patient has a known hypersensitivity or contraindication to aspirin, clopidogrel, nitinol, or contrast dye that cannot be adequately premedicated.
  • Patient is pregnant or breast-feeding.

结局指标

主要结局

The primary endpoint of the study is major adverse event (MAE) rate at the 9-month follow-up.

次要结局

  • Additional endpoints include acute procedure and hemodynamic success, secondary patency, 9-month restenosis rate based on ultrasound examination, and 9-month functional status improvement.

研究者

申办方类型
Industry

相似试验